Evans Blue Acts as a Selective Inhibitor of CaMKII‐α to Impede the Progression of TCL Identified by HTS DOI Creative Commons

Jianru Tian,

Aiqin Zhang,

Lansong Li

и другие.

Cancer Science, Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

T-cell lymphoma (TCL) poses a significant challenge in clinical oncology, characterized by its aggressive behavior and resistance to conventional therapies. Despite considerable research efforts, the prognosis for TCL patients remains poor, primarily due lack of effective therapeutic strategies that can inhibit tumor progression metastasis. In this study, we identified CaMKII-α as potential target TCL. To explore role pathogenesis, investigated effects on cell lines. Protein expression levels within PI3K-AKT signaling pathway were assessed using western blot analysis. Through siRNA-mediated gene silencing, downregulated monitored proliferation. Furthermore, Evans Blue (IC50 = 197.1 nM) selective small-molecule inhibitor through high-throughput screening (HTS). demonstrated tumor-suppressive effects, potentially inhibiting proliferation via regulation pathway. Notably, antitumor effect was comparable observed with genetic ablation, highlighting novel strategy treatment

Язык: Английский

Evans Blue Acts as a Selective Inhibitor of CaMKII‐α to Impede the Progression of TCL Identified by HTS DOI Creative Commons

Jianru Tian,

Aiqin Zhang,

Lansong Li

и другие.

Cancer Science, Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

T-cell lymphoma (TCL) poses a significant challenge in clinical oncology, characterized by its aggressive behavior and resistance to conventional therapies. Despite considerable research efforts, the prognosis for TCL patients remains poor, primarily due lack of effective therapeutic strategies that can inhibit tumor progression metastasis. In this study, we identified CaMKII-α as potential target TCL. To explore role pathogenesis, investigated effects on cell lines. Protein expression levels within PI3K-AKT signaling pathway were assessed using western blot analysis. Through siRNA-mediated gene silencing, downregulated monitored proliferation. Furthermore, Evans Blue (IC50 = 197.1 nM) selective small-molecule inhibitor through high-throughput screening (HTS). demonstrated tumor-suppressive effects, potentially inhibiting proliferation via regulation pathway. Notably, antitumor effect was comparable observed with genetic ablation, highlighting novel strategy treatment

Язык: Английский

Процитировано

0